{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:16:19Z","timestamp":1789654579427,"version":"4.0.1"},"reference-count":71,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences"},{"DOI":"10.13039\/501100011699","name":"Siemens Healthineers","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011699","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background\/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly attracting growing concern around the world. While there has been progress in the development of pharmacologic treatments, lifestyle and dietary interventions remain as the first-line approach for management. This scoping review aimed to identify dietary strategies for managing MASLD and to highlight current research gaps and challenges. Methods: A systematic search of PubMed and Science Direct was conducted up to 10 July 2025, for relevant studies on dietary modifications and MASLD. Data extracted included types of interventions, outcomes related to liver health, and research limitations. Results: Dietary interventions were shown to consistently improve hepatic and metabolic outcomes. In a randomized controlled trial of 12 weeks (n = 259), a Mediterranean diet reduced hepatic steatosis by 39% and improved insulin sensitivity. A calorie-restricted lifestyle program in adults with MASLD (n = 196) reduced liver fat by 25% over 52 weeks. Resistant starch supplementation (n = 200) lowered intrahepatic triglyceride content by 8% through gut microbiome modulation. A pilot RCT of medically tailored meals in cirrhosis (n = 40) reduced ascites symptoms and improved quality of life. Finally, prebiotic supplementation in MASLD (n = 200) lowered systemic inflammation and increased immune-regulating microbes. In contrast, Western dietary patterns and ultra-processed foods were consistently linked to lipotoxicity and inflammation. Conclusions: Dietary interventions remain critical for the management of chronic liver disease and continue to play a vital role even as pharmacotherapy options emerge. Further research should explore precision nutrition and microbiome-based therapies while also addressing the methodological limitations like the underutilization of causal inference frameworks. Finally, it is also important to consider culturally tailored interventions to account for barriers in access and equity in underserved populations.<\/jats:p>","DOI":"10.3390\/nu17213491","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:51:43Z","timestamp":1762451503000},"page":"3491","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dietary Interventions in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review of Evidence, Mechanisms, and Translational Challenges"],"prefix":"10.3390","volume":"17","author":[{"given":"Alejandra","family":"Paredes-Marin","sequence":"first","affiliation":[{"name":"Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"He","sequence":"additional","affiliation":[{"name":"Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3968-5030","authenticated-orcid":false,"given":"Xiaotao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Cancer Prevention and Control, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"D\u00edaz Carnicero, J., Saur\u00ed-Ferrer, I., Redon, J., Navarro, J., Fern\u00e1ndez, G., Hurtado, C., Ferreira, K., Alvarez-Ortega, C., G\u00f3mez, A., and Martos-Rodr\u00edguez, C.J. (2025). Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14072441"},{"key":"ref_4","unstructured":"(2025, September 18). FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"key":"ref_5","unstructured":"(2025, August 19). FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019, Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101013","DOI":"10.1016\/j.xkme.2025.101013","article-title":"Utilization Trends of Dual GIP\/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes","volume":"7","author":"Hansrivijit","year":"2025","journal-title":"Kidney Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cpt.3606","article-title":"Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions","volume":"117","author":"Wu","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Jurek, J.M., Zablocka-Sowinska, K., Clavero Mestres, H., Reyes Guti\u00e9rrez, L., Camaron, J., and Auguet, T. (2025). The Impact of Dietary Interventions on Metabolic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Comorbid Conditions, Including Obesity and Type 2 Diabetes. Nutrients, 17.","DOI":"10.3390\/nu17071257"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia, 67, 2375\u20132392.","DOI":"10.1007\/s00125-024-06196-3"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s13679-019-00345-1","article-title":"Nonalcoholic Fatty Liver Disease and Obesity Treatment","volume":"8","author":"Brunner","year":"2019","journal-title":"Curr. Obes. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e0791","DOI":"10.1097\/HC9.0000000000000791","article-title":"Mediterranean diet and associated metabolite signatures in relation to MASLD progression: A prospective cohort study","volume":"9","author":"Wang","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Arita, V.A., Cabezas, M.C., Hern\u00e1ndez Vargas, J.A., Trujillo-C\u00e1ceres, S.J., Mendez Pernicone, N., Bridge, L.A., Raeisi-Dehkordi, H., Dietvorst, C.A.W., Dekker, R., and Uriza-Pinz\u00f3n, J.P. (2025). Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of randomized controlled trials. BMC Med., 23.","DOI":"10.1186\/s12916-025-04320-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8248","DOI":"10.1039\/D4FO01461H","article-title":"A systematic review and meta-analysis of randomized controlled trials: Effects of mediterranean diet and low-fat diet on liver enzymes and liver fat content of NAFLD","volume":"15","author":"Xiong","year":"2024","journal-title":"Food Funct."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lin, X., Wang, S., and Huang, J. (2024). The effects of time-restricted eating for patients with nonalcoholic fatty liver disease: A systematic review. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1307736"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Oh, J.H., Yoon, E.L., Park, H., Lee, S., Jo, A.J., Cho, S., Kwon, E., Nah, E.-H., Lee, J.-H., and Park, J.H. Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease. J. Hepatol., 2025. in press.","DOI":"10.1016\/j.jhep.2025.06.005"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/jgh.16723","article-title":"Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis","volume":"39","author":"Chee","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Trenell","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Castelnuovo, G., Perez-Diaz-Del-Campo, N., Rosso, C., Armandi, A., Caviglia, G.P., and Bugianesi, E. (2024). A Healthful Plant-Based Diet as an Alternative Dietary Approach in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease. Nutrients, 16.","DOI":"10.3390\/nu16132027"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: The DIRECT PLUS randomised controlled trial","volume":"70","author":"Rinott","year":"2021","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.14309\/ajg.0000000000002508","article-title":"A Study of Dietary Patterns Derived by Cluster Analysis and their Association with Nonalcoholic Fatty Liver Disease Severity among Hispanic Patients","volume":"119","author":"Zhang","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11695-008-9549-0","article-title":"Nutritional assessments of patients with non-alcoholic fatty liver disease","volume":"20","author":"Kim","year":"2010","journal-title":"Obes. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jada.2011.10.007","article-title":"The role of diet and nutrient composition in nonalcoholic Fatty liver disease","volume":"112","author":"McCarthy","year":"2012","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.jhepr.2021.100256","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet\u2014A randomised controlled trial","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.14218\/JCTH.2021.00494","article-title":"Current Evidence Concerning Effects of Ketogenic Diet and Intermittent Fasting in Patients with Nonalcoholic Fatty Liver","volume":"10","author":"Sripongpun","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1073\/pnas.1922344117","article-title":"Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease","volume":"117","author":"Luukkonen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e70099","DOI":"10.1002\/jgh3.70099","article-title":"Effect of a Ketogenic Diet on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Progression: A Randomized Controlled Trial","volume":"9","author":"Chirapongsathorn","year":"2025","journal-title":"JGH Open"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Dy\u0144ka, D., Rodze\u0144, \u0141., Rodze\u0144, M., \u0141ojko, D., Kraszewski, S., Ibrahim, A., Hussey, M., Deptu\u0142a, A., Grzywacz, \u017b., and Ternianov, A. (2024). Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD\/MAFLD). J. Clin. Med., 13.","DOI":"10.3390\/jcm13164857"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Emanuele, F., Biondo, M., Tomasello, L., Arnaldi, G., and Guarnotta, V. (2025). Ketogenic Diet in Steatotic Liver Disease: A Metabolic Approach to Hepatic Health. Nutrients, 17.","DOI":"10.3390\/nu17071269"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ajcnut.2024.01.009","article-title":"Increased low-density lipoprotein cholesterol on a low-carbohydrate diet in adults with normal but not high body weight: A meta-analysis","volume":"119","author":"Norwitz","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100495","DOI":"10.1016\/j.ajpc.2023.100495","article-title":"Dramatic elevation of LDL cholesterol from ketogenic-dieting: A Case Series","volume":"14","author":"Schmidt","year":"2023","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_33","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"nzy077","DOI":"10.1093\/cdn\/nzy077","article-title":"Ultra-Processed Foods: Definitions and Policy Issues","volume":"3","author":"Gibney","year":"2019","journal-title":"Curr. Dev. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Geladari, E.V., Kounatidis, D., Christodoulatos, G.S., Psallida, S., Pavlou, A., Geladari, C.V., Sevastianos, V., Dalamaga, M., and Vallianou, N.G. (2025). Ultra-Processed Foods and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): What Is the Evidence So Far?. Nutrients, 17.","DOI":"10.3390\/nu17132098"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Garc\u00eda, S., Monserrat-Mesquida, M., Ugarriza, L., Casares, M., G\u00f3mez, C., Mateos, D., Angullo-Mart\u00ednez, E., Tur, J.A., and Bouzas, C. (2025). Ultra-Processed Food Consumption and Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): A Longitudinal and Sustainable Analysis. Nutrients, 17.","DOI":"10.3390\/nu17030472"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1665-2681(19)31253-0","article-title":"Survey of health status, nutrition and geography of food selection of chronic liver disease patients","volume":"13","author":"Leslie","year":"2014","journal-title":"Ann. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cld.687","article-title":"Clinical studies investigating the effect of vitamin E therapy in patients with NASH","volume":"11","author":"Larion","year":"2018","journal-title":"Clin Liver Dis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cansan\u00e7\u00e3o, K., Citelli, M., Carvalho Leite, N., L\u00f3pez de las Hazas, M.-C., D\u00e1valos, A., Tavares do Carmo, M.d.G., and Peres, W.A.F. (2020). Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial. Nutrients, 12.","DOI":"10.3390\/nu12113372"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lee, C.-H., Fu, Y., Yang, S.-J., and Chi, C.-C. (2020). Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis. Nutrients, 12.","DOI":"10.3390\/nu12092769"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clnu.2025.05.013","article-title":"Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials","volume":"50","author":"Kim","year":"2025","journal-title":"Clin. Nutr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhang, X., Irajizad, E., Hoffman, K.L., Fahrmann, J.F., Li, F., Seo, Y.D., Browman, G.J., Dennison, J.B., Vykoukal, J., and Luna, P.N. (2023). Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: Insights from the BE GONE trial. EBioMedicine, 98.","DOI":"10.1016\/j.ebiom.2023.104873"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.cmet.2023.07.004","article-title":"Vive la resistant starch: A potential treatment for metabolic dysfunction-associated steatohepatitis","volume":"35","author":"Zhang","year":"2023","journal-title":"Cell Metab."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Feehan, J., Mack, A., Tuck, C., Tchongue, J., Holt, D.Q., Sievert, W., Moore, G.T., de Courten, B., and Hodge, A. (2023). Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease-A Single Blinded Crossover Trial. Nutrients, 15.","DOI":"10.21203\/rs.3.rs-2641051\/v1"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e233513","DOI":"10.1001\/jamanetworkopen.2023.3513","article-title":"Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101363","DOI":"10.1016\/j.jhepr.2025.101363","article-title":"Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD","volume":"7","author":"Moolla","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Reshef, N., Gophna, U., Reshef, L., Konikoff, F., Gabay, G., Zornitzki, T., Knobler, H., and Maor, Y. (2024). Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)-A Randomized Pilot Trial. Nutrients, 16.","DOI":"10.3390\/nu16111571"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ahn, S.B., Jun, D.W., Kang, B.-K., Lim, J.H., Lim, S., and Chung, M.-J. (2019). Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-42059-3"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"17562848231174299","DOI":"10.1177\/17562848231174299","article-title":"The effect of synbiotics in patients with NAFLD: A systematic review and meta-analysis","volume":"16","author":"Cai","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Xue, L., Deng, Z., Luo, W., He, X., and Chen, Y. (2022). Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.759306"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/1744666X.2021.1935877","article-title":"The pathogenic oral-gut-liver axis: New understandings and clinical implications","volume":"17","author":"Imai","year":"2021","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e94416","DOI":"10.1172\/jci.insight.94416","article-title":"Microbiota, cirrhosis, and the emerging oral-gut-liver axis","volume":"2","author":"Acharya","year":"2017","journal-title":"JCI Insight"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Lei, Y., Li, S., He, M., Ao, Z., Wang, J., Wu, Q., and Wang, Q. (2023). Oral Pathogenic Bacteria and the Oral-Gut-Liver Axis: A New Understanding of Chronic Liver Diseases. Diagnostics, 13.","DOI":"10.3390\/diagnostics13213324"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00520","DOI":"10.14309\/ctg.0000000000000520","article-title":"Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled Trial","volume":"13","author":"Kamata","year":"2022","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.hlife.2025.01.001","article-title":"The crucial function of gut microbiota on gut\u2013liver repair","volume":"3","author":"Wang","year":"2025","journal-title":"hLife"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jhep.2024.08.008","article-title":"Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids","volume":"82","author":"Zhang","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2020.04.030","article-title":"Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum","volume":"73","author":"Glass","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez, T., Vi\u00f1uela, M., Vidal, C., and Barrera, F. (2022). Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263931"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/GME.0000000000000647","article-title":"Randomized clinical trial: Benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease","volume":"23","author":"Rezende","year":"2016","journal-title":"Menopause"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/aje\/kwae222","article-title":"Invited commentary: Target trial emulation-a call for more widespread use","volume":"194","author":"Anderson","year":"2025","journal-title":"Am. J. Epidemiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e40095","DOI":"10.1097\/MD.0000000000040095","article-title":"Exploring causal associations between dietary intake and liver diseases: A bidirectional Mendelian randomization study","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Domos\u0142awska-\u017byli\u0144ska, K., \u0141opatek, M., Krysi\u0144ska-Pisarek, M., and Sugay, L. (2023). Barriers to Adherence to Healthy Diet and Recommended Physical Activity Perceived by the Polish Population. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010022"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/gastro\/goaa059","article-title":"Medically tailored meals for the management of symptomatic ascites: The SALTYFOOD pilot randomized clinical trial","volume":"8","author":"Tapper","year":"2020","journal-title":"Gastroenterol. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"146502","DOI":"10.1155\/2014\/146502","article-title":"Understanding barriers and facilitators to healthy eating and active living in rural communities","volume":"2014","author":"Seguin","year":"2014","journal-title":"J. Nutr. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3350\/cmh.2024.0562","article-title":"Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on \u201cDifferences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study\u201d","volume":"30","author":"Bae","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/15598276211006342","article-title":"Cultural Relevancy of Culinary and Nutritional Medicine Interventions: A Scoping Review","volume":"16","author":"Villalona","year":"2022","journal-title":"Am. J. Lifestyle Med."},{"key":"ref_71","unstructured":"(2025, October 08). REACH Program Impact, Available online: https:\/\/www.cdc.gov\/reach\/php\/program-impact\/."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/21\/3491\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:26:46Z","timestamp":1785313606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/21\/3491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":71,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["nu17213491"],"URL":"https:\/\/doi.org\/10.3390\/nu17213491","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}